Understanding each patient's individual story is vital in the transition to patient-centered care. Additionally, matching patients with physicians of the same race and background can boost comfortability among patients.
Understanding each patient's individual story is vital in the transition to patient-centered care. Additionally, matching patients with physicians of the same race and background can boost comfortability among patients, said Karen Winkfield, MD, PhD, associate director for community outreach and engagement at Wake Forest Baptist Health and associate professor of radiation oncology at Wake Forest University.
Transcript
AJMC®: What is the chief message you hope to share with the attendees at Patient-Centered Oncology Care® 2020?
Dr Winkfield: I am a huge advocate of listening to your patients. Every patient who walks in the door, every single one of them has their own story. So, we cannot lump, we can't split. We just have to see the person who's in front of us, and that requires taking a little time sometimes.
We might just have to say, "I want to get to know this patient so that I can give them the best care so that we can be..." Patient-centered means that we have to stop and see the individual who's in front of us and listen to the communities and find out what their resources are, find out who their support systems are, and meet those individuals right where they are.
AJMC®: Your work on the issue of cancer disparities has highlighted the challenges of attracting underrepresented minorities into oncology and biomedical research. Can you discuss why changing the oncology workforce is essential to reducing disparities in cancer outcomes?
Dr Winkfield: There have been several of us over the past several decades who have recognized that workforce diversity is really an important component of ensuring that patients have people who look like them, who have similar backgrounds as them, so they feel comfortable.
We know that, particularly in this era now where there's been more and more attention paid to some of the racial injustices that have happened over time, that frequently individuals who are from backgrounds that are traditionally underrepresented don't feel comfortable walking into cancer centers or into hospitals or into doctors' offices.
In fact, if you look back 50 years ago, there was segregation, and so they would not have been allowed to go into some of these institutions. So, it really is important to make sure that our workforce, our oncology workforce, and our primary care workforce is representing the individuals that we're trying to care for. We have a lot of work to do. The pipeline is not not strong.
You mentioned other STEM [science, technology, engineering, math] careers. It's not just about clinicians. I would love to have lots and lots of physicians of color, but we also need other individuals, whether it be nurses or scientist, researchers. These are all important individuals and components of what it means to really take care of individuals who are from backgrounds that are traditionally disenfranchised.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Frameworks for Advancing Health Equity: Trans and Gender Diverse Health Care
June 28th 2024Charlie Borowicz, manager of trans and gender diverse health at Allegheny Health Network, shares how the program offers comprehensive patient-first care to those in the LGBTQ+ and gender diverse community.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More